Humulin M3 (30/70) Kwikpen

Humulin M3 (30/70) Kwikpen is a pre‑filled, disposable pen injector that contains insulin human in a premixed formulation of 30% rapid‑acting and 70% protaminated insulin. The product is authorized for prescription use in the European Union and is administered subcutaneously. It provides a convenient delivery system for patients requiring basal‑bolus insulin therapy for diabetes management. It is designed for dosing and eliminates the need for vial and syringe preparation.

Humulin M3 (30/70) Kwikpen is indicated for the management of hyperglycemia in adults with diabetes.

- Type 1 diabetes mellitus when a basal‑bolus regimen is required. - Type 2 diabetes mellitus inadequately controlled with oral agents alone. - Patients who need a convenient premixed insulin to simplify injection schedules. - Adjunct therapy during periods of increased insulin demand, such as illness or stress. - Use in combination with lifestyle measures, including diet and exercise, to achieve glycemic targets.

Adverse reactions to Humulin M3 (30/70) Kwikpen are reported in clinical practice and may vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient. - Injection site reactions such as redness, swelling, or itching. - Weight gain associated with improved glycemic control. - Transient lipodystrophy at the injection site.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions, including urticaria, angioedema, or anaphylaxis. - Hypersensitivity with eosinophilia or serum sickness–like symptoms. - Persistent or painful lipohypertrophy that interferes with insulin absorption.

Before initiating Humulin M3 (30/70) Kwikpen, healthcare providers should evaluate patient-specific factors and monitor for conditions that could affect insulin therapy.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review history of hypoglycemia unawareness or recurrent severe episodes. - Consider pregnancy status; insulin requirements may change during gestation. - Avoid use in patients with known hypersensitivity to human insulin or excipients. - Educate patients on proper injection technique to reduce lipodystrophy risk. - Monitor blood glucose regularly and adjust dose based on fasting and post‑prandial values.

Humulin M3 (30/70) Kwikpen can interact with other medicines that influence glucose metabolism or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise insulin requirements. - Thiazide diuretics, which can affect glucose tolerance. - Alcohol consumption, which can cause delayed hypoglycemia.